Syndax reports preliminary 2025 Revuforj $125M, Niktimvo $152M net rev, cash $394M

Syndax Pharmaceuticals Inc

2025-FY EPS reported -$3.29 revenue$172,352,000

Revuforj preliminary net revenue $44M (Q4) and $125M (FY), up 38% QoQ.
Niktimvo preliminary net revenue $56M (Q4) and $152M (FY); Syndax's 50% profit share expected ~25-30% of net rev.
Cash, equivalents and marketable securities ~$394M at year-end 2025 (unaudited).
2026 R&D + SG&A expense guidance ~$400M (excl. $50M non-cash stock comp); company funded to profitability.
Key 2026 milestones: complete IPF trial enrollment, advance frontline Phase 3 revumenib trials, initiate MF proof-of-principle.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.